Last reviewed · How we verify
A Phase III, Double-Blind, Placebo Controlled Trial of Gemcitabine Plus Placebo Versus Gemcitabine Plus R115777 in Patients With Advanced Pancreatic Cancer
The purpose of this study is to compare the effectiveness of gemcitabine with or without tipifarnib (R115777) in patients who have advanced pancreatic cancer.
Details
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 688 |
| Start date | 1999-11 |
| Completion | 2003-11 |
Conditions
- Pancreatic Neoplasms
Interventions
- Gemcitabine with R115777
- Gemcitabine with Placebo
Primary outcomes
- Overall survival of patients with advanced pancreatic cancer after treatment with gemcitabine with or without R115777. — From the date of randomization to the date of death or to the last followup date for patients who were still alive at the clinical cutoff date (ie, for up to 5 years)